title: Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis.
abstract: Pyoderma gangrenosum (PG) is an uncommon extra-intestinal manifestation of inflammatory bowel disease (IBD). Despite limited published literature, biologics have caused a paradigm shift in the management of this difficult-to-treat skin condition. The clinical data and outcomes of three patients with active ulcerative colitis and concurrent PG treated with biologics (infliximab two and adalimumab one) are reviewed in this report. Biologics were added because of the sub-optimal response of the colonic symptoms and skin lesions to parenteral hydrocortisone therapy. All three patients showed a dramatic response to the addition of the biologics. In view of the rapid healing of the skin lesions, superior response rate, and the additional benefit of improvement in the underlying colonic disease following treatment, anti-tumor necrosis factor blockers should be considered as a first line therapy in the management of PG with underlying IBD.
authors: Department of Gastroenterology, GB Pant Hospital, New Delhi, India.
authors: K
authors: K
authors: Arivarasan
authors: Department of Gastroenterology, GB Pant Hospital, New Delhi, India.
authors: Vaishali
authors: V
authors: Bhardwaj
authors: Department of Gastroenterology, GB Pant Hospital, New Delhi, India.
authors: Sukrit
authors: S
authors: Sud
authors: Department of Gastroenterology, GB Pant Hospital, New Delhi, India.
authors: Sanjeev
authors: S
authors: Sachdeva
authors: Department of Gastroenterology, GB Pant Hospital, New Delhi, India.
authors: Amarender Singh
authors: AS
authors: Puri
keywords: Biological products; Colitis, ulcerative; Extra-intestinal manifestations; Inflammatory bowel disease; Pyoderma gangrenosum